XY Capital Ltd Acquires New Shares in argenex SE $ARGX

XY Capital Ltd acquired a new stake in shares of argenex SE (NASDAQ:ARGX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 606 shares of the company’s stock, valued at approximately $510,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Capital World Investors boosted its position in argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after acquiring an additional 8,422 shares during the period. M&T Bank Corp raised its position in shares of argenex by 20,977.7% during the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares during the period. Wellington Management Group LLP raised its position in argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after buying an additional 324,653 shares during the period. Bank of America Corp DE raised its position in argenex by 1.9% during the third quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock valued at $252,525,000 after buying an additional 6,259 shares during the period. Finally, Two Sigma Investments LP raised its position in argenex by 570.3% during the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after buying an additional 250,278 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Price Performance

ARGX stock opened at $898.94 on Friday. The business has a fifty day moving average price of $809.08 and a 200 day moving average price of $811.60. The stock has a market capitalization of $55.91 billion, a price-to-earnings ratio of 40.02, a P/E/G ratio of 1.32 and a beta of 0.47. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62.

argenex (NASDAQ:ARGX) last released its earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The company had revenue of $1.31 billion during the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%. On average, equities analysts expect that argenex SE will post 26.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Wedbush restated an “outperform” rating and set a $1,000.00 target price on shares of argenex in a research note on Thursday. HC Wainwright boosted their price objective on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Oppenheimer lowered their price objective on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research report on Thursday, April 2nd. Finally, Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, argenex has a consensus rating of “Moderate Buy” and an average price target of $1,019.50.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.